首页>
外文期刊>Prescrire international
>'Targeted therapies' for metastatic colorectal cancer - A weak or uncertain effect on survival, with a risk of serious adverse effects
【24h】
'Targeted therapies' for metastatic colorectal cancer - A weak or uncertain effect on survival, with a risk of serious adverse effects
In patients with metastatic colorectal cancer "targeted therapies" are sometimes proposed, including anti-VEGF (vascular endothelial growth factor) agents such as aflibercept, bevacizumab and ramucirumab; or anti-EGFR (epidermal growth factor receptor) agents such as cetuximab and panitumumab. Do these drugs have an effect on survival in patients with inoperable metastatic colorectal cancer? What are their adverse effects? To answer these questions, we reviewed the available evidence, using the standard Prescrire methodology.
展开▼
